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ABSTRACT
The transcription factor NF-Y is a trimerwith histone-
like subunits that binds and activates CCAAT-
containing promoters. NF-Y controls the expression
of several key regulators of the cell cycle. In this
study, we examined the functional and molecular
effects of NF-YB knockdown. Cell cycle progression
is affected with a G2/M-specific depletion. This is
due to the inability of activation of G2/M-specific
genes, as evidenced by expression profiling, RT-PCR
and ChIP data. Surprisingly, apoptosis is also
observed, with Caspase 3/7/8 cleavage. A role of
p53 and Bcl-2 family members is important. NF-YB
inactivation is sufficient to functionally activate p53,
in the absence of DNA damage. Failure to maintain a
physiologic level of CCAAT-dependent transcription
of anti-apoptotic genes contributes to impairment of
Bax/Bcl-2 and Bax/Bcl-XL ratios. Our data highlight
the importance of fine balancing the NF-Y-p53 duo
for cell survival by (i) maintaining transcription of
anti-apoptotic genes and (ii) preventing p53 activa-
tion that triggers the apoptotic cascade.
INTRODUCTION
The CCAAT-binding factor NF-Y is a mammalian
transcription factor that binds to CCAAT boxes in the
promoters of a wide variety of genes. The CCAAT box is a
common promoter element, and, in higher eukaryotes, it is
found in 60% of tissue-specific, housekeeping and cell
cycle-regulatory genes (1,2). In vitro and in vivo assays
clearly demonstrated that NF-Y is the major CCAAT-
binding activator (3,4). NF-Y is a heterotrimeric complex
composed of three subunits, A, B and C, which are all
essential for CCAAT binding (5,6). NF-YB and NF-YC
contain histone fold motifs (HFMs) common to all core
histones; NF-YB and NF-YC dimerization is essential for
NF-YA association and sequence-specific DNA binding
(7 and references therein). NF-Y is required to organize
the chromatin in proximity of transcriptional start sites,
thereby enabling recruitment of coactivators (8,9).
NF-Y controls the expression of several key regulators
of the cell cycle (10–16). A bioinformatic analysis of cell
cycle promoters showed a remarkable and specific abun-
dance of CCAAT boxes in promoters regulated during
the G2/M phase (17). Chip assays clearly demonstrated
that NF-Y interactions with cell cycle regulated promoters,
such as CDC2, CDC25A/B/C, cyclin A2, cyclin B1/B2 and
E2F1, is highly dynamic through the cell cycle (18).
The three subunits are regulated at different levels.
NF-YA has two major isoforms generated by alternative
splicing, variously expressed in different cell types (19).
NF-YC also has different isoforms that are regulated in a
cell-specific way (Salvatoni,L. and Mantovani,R., unpub-
lished data). The nuclear localization of NF-YC is cell
cycle regulated and depends on the presence of its histone
fold partner NF-YB (20). NF-YA is not ubiquitously
expressed, being undetectable in adult skeletal muscle and
heart tissues, whereas the NF-YB/NF-YC heterodimer is
expressed in most tissues (21). Another level of regulation
involves the acetylation of NF-YB (22) and the acetylation
and phosphorylation of NF-YA [(22), Caretti,G. and
Mantovani,R., unpublished data].
NF-Y is also involved in the modulation of the activity
of cell cycle promoters in response to DNA damage
(14,23), through wild-type p53-dependent transcriptional
inhibition (16,24). p53 forms a complex with NF-Y on
CCAAT box-containing promoters, and upon DNA
damage, this complex can recruit histone-deacetylases
(HDACs) and release acetyltransferases (HATs), causing
a repression of cell cycle promoters (24). Interestingly,
mutant p53/NF-Y complexes have the opposite effect on
transcription upon DNA damage, that is, transactivation
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of proliferative genes, and aberrant cell cycle regu-
lation (25,26). Finally, a recent genome-wide mRNA
expression profiling of the transformation process verified
that p53-mediated transcriptional repression of several
targets is dependent on the activities of NF-Y, p21 and
E2F (27).
Attempts to define the role of NF-Y in cell cycle
regulation focused on NF-YA. A conditional deletion of
both NF-YA alleles in primary cultures of mouse
embryonic fibroblast cells led to a complete block in cell
cycle progression (28). Expression of the dominant
negative NF-YA mutant in mouse NIH 3T3 fibroblasts
caused the cells to grow slower, with a modest increase in
the time required for the cells to complete the S phase of
the cell cycle (29).
We decided to sytematically examine the functional
and transcriptional effects of abrogation of the NF-YB
subunit by RNAi, using FACS, IF, gene expression
profiling, RT-PCR and ChIP analysis in wt p53
HCT116 cells and in their E6 expressing counterpart, in
which p53 is functionally inactivated.
MATERIALS AND METHODS
Cell lines and drugs
The human colon carcinoma HCT116 and HCT116/E6
were generously provided by Bert Volgestein (Johns
Hopkins University School of Medicine, Baltimore, MD,
USA). The cells were maintained as described previously
(30). SW1353 human chondrosarcoma cells (ATCC, USA)
were cultured in Leibovitz’s L-15 medium containing 10%
fetal bovine serum (Euroclone), 2mM glutamine, 100 IU/
ml penicillin and 100mg/ml streptomycin according to the
ATCC protocol.
For caspase inhibitor treatments, cells were treated with
25 mM ZVAD-fmk (Sigma-Aldrich) 1 h before and during
the 48 h of siRNA transfection.
Small interfering RNA (siRNA)
HCT116 and HCT116/E6 cells were transfected (Lipofec-
tamine 2000, Invitrogen) with 200 nM of paired NF-YB
and non-targeting control small interfering RNA (siRNA)
designed by Ambion, or with scramble and NF-YB
shRNAs designed by Sigma-Aldrich.
NF-YB siRNAs. NF-YB1: sense-GGAAGUCAUUAUG
UUAUACtt, antisense- GUAUAACAUAAUGACU
UCCtc;
NF-YB2: sense-GGACAGCAUGAAGGAUCAUtt,
antisense-AUGAUCAUUCAUGCUGUCCtc;
NF-YB3: sense- GGCAUUUACUAACCAGUUAtt,
antisense-UAACUGGUUAGUAAAUGCCtc.
NF-YB shRNA.
(i) CCGGGCTATGTCTACTTTAGGCTTTCTCGA
GAAAGCCTAAAGTAGACATAGCTTTTT;
(ii) CCGGGCAAGTGAAAGGTGCCATCAACTCG
AGTTGATGGCACCTTTCACTTGCTTTTT.
Cells were monitored by microscopy at 24, 48 and 72 h.
Total extracts and RNA were prepared after 48 h upon
siRNA transfection.
Immunoblotting
For immunoblotting, equivalent amount of total extracts
were resolved by SDS–PAGE, electrotransferred to
nitrocellulose membrane and immunoblotted with
NF-YB, NF-YA and NF-YC-purified rabbit polyclonal
antibodies, anti-CycB1 and Cyc-A (Cell Signaling), anti-
p53 (Active Motif), anti-phospo-Ser15 p53 (Cell
Signaling), anti-Bax (N-20, S.Cruz); anti-CytC (S.Cruz)
and anti-actin (Sigma).
Immunofluorescence
HCT116 cells were mock and NF-YB siRNA transfected
for 48 h, then immunofluorescence assays were performed
as described previously (30) with the following antibodies:
anti-cleaved caspases 3-6-7-8 (Cell Signaling), anti-p53
Ab-7 (Calbiochem), anti-phospho histone H2AX
(Ser-139) (Upstate) and Hoechst. Immunofluorescence
was examined with a Zeiss AxioSkop 40 fluorescence
microscope (Carl Zeiss, Germany) and the images
collected with an AxioCam HRc camera and AxioVision
version 3.1 software package.
Plasmids and transfections
A total of 2 105 HCT116 cells were transiently
transfected with Lipofectamine 2000 (Invitrogen) using
the indicated doses of DN-YA and NF-Y, 200 ng of BI-1
or Bcl-2 luciferase reporter, 50 ng of b-galactosidase and
carrier plasmid to keep the total DNA concentration
constant at 800 ng. Cells were recovered 24 h after
transfection, resuspended in lysis buffer (1% Triton
X-100, 25mM glycil-glycine, 15mM MgSO4, 4mM
EGTA) for luciferase activities. b-Galactosidase was
assayed to control for transfection efficiency. Three
independent transfections in duplicate were performed.
Chromatin immunoprecipitation
Chromatin immunoprecipitations were essentially per-
formed as described previously (24,30). Chromatin was
prepared upon 48 h of control siRNA or NF-YB siRNA
transfection. CcnB2, Cdc2 and Cdc25C primers were
described in Ref. (30). Oligonucleotide sequences are
indicated in Supplementary Data.
Gene expression profiling and data analysis
Gene expression profiling was performed as described in
Ref. (31). All expression values for the genes in the MAS
5.0 absolute analyses were determined using the global
scaling option. MAS 5.0 comparison algorithm was used
for pairwise analysis. Gene Ontology enrichment P-values
were computed according to the hypergeometric distribu-
tion. GO terms have been ranked by increasing P-value;
a ‘ratio’ has been calculated between the number of genes
belonging to the GO term, in the sample-set versus the
universe-set. Only terms with (i) P-value <1.00E03 and
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(ii) ratio >2 and (iii) number of sample genes >4 have
been displayed; in addition, redundant terms were
manually removed, and terms were grouped by macro-
categories (including terms from all the three GO
partitions: MF, BP and CC). Differentially Expressed
Genes (DEGs) were selected using SAM method (as
provided by R package DEDS). The parameter ‘delta’ was
set to 0.4, with an estimated FDR (False Discovery Rate)
= 25% (32). A detailed list of all the genes identified in
this study is available upon request.
Reverse Transcription (RT)-PCR analysis
RNA was extracted using the RNeasy kit (Qiagen, Hilden,
Germany), according to the manufacturer’s protocol,
from HCT116 and HCT116/E6 control or NF-YB
siRNA-transfected cells. For cDNA synthesis, 5 mg of
RNA was retrotranscribed with a Moloney murine
leukemia virus reverse transcriptase (Finzymes).
Semiquantitative PCR analysis was performed with
oligonucleotides indicated in Supplementary Data.
CcnB2, Cdc25C and Bax primers were described pre-
viously (30). Glyceraldehyde 3-phosphate dehydrogenase
control RT-PCR was performed with standard oligonu-
cleotides. Oligonucleotide sequences are indicated in
Supplementary Data.
Flow cytometric cell cycle analysis
Cells were harvested after 48 h of siRNA transfection and
DNA distribution analysis of propidium–iodide-stained
cells was performed by an Epics cytofluorimeter (Beckman
Coulter). Apoptotic cells were identified by fluorescence-
activated cell sorting (FACS) using Annexin V-PE
conjugate (Invitrogen) following the protocol of the
manufacturer.
Isolation of cytosolic fraction by digitonin lysis method
A total of 2 105 HCT116 cells were transiently
transfected with 1 mg of expression plasmids for each
NF-Y subunits. After 24 h the cells were incubated
overnight with Adriamycin (0.2 and 0.5 mg/ml) and were
then harvested. After two washes with PBS, the pellet was
resuspended in digitonin lysis buffer (75mM NaCl, 1mM
NaH2PO4, 8mM Na2HPO4, 250mM sucrose and 190
mg/ml of digitonin) containing protease inhibitors and
incubated on ice for 5min. The releasate was centrifuged
at 15 000 r.p.m. at 48C for 30min and used for western
blotting using mouse cytochrome c antibody (S. Cruz).
RESULTS
Silencing of NF-YB by RNA interference
We designed three RNA-interference (RNAi) oligos to
disrupt the function of the NF-YB subunit (Figure 1A);
transfections of HCT116 cells with two of these siRNAs
—NF-YB2 and NF-YB3— resulted in a significant and
reproducible degradation of NF-YB mRNA, as shown by
RT-PCR analysis (Figure 1B, left panel), and protein,
as judged by western blotting (Figure 1B, right panel).
The degree of knockdown was 75–95%. The actin protein
and GAPDH mRNA were used as internal controls
(Figure 1B, right and left panels, respectively). We
analyzed the effect of NF-YB silencing on the transcrip-
tion and expression of the other NF-Y subunits. We
noticed increased transcription of NF-YC, and no changes
Figure 1. NF-YB RNAi in HCT116 cells. (A) Three siRNA were
designed on human NF-YB gene. Black boxes represent exons;
red boxes indicate targeted exons. (B) Left panel: RT-PCR analysis
of NF-YB and GAPDH mRNA transcripts in negative control and
NF-YB1-2-3-silenced cells. Right panel: western blot analysis of
HCT116 total extracts with anti-NF-YB and anti-actin antibodies,
transfected with control and NF-YB siRNAs. (C) RT-PCR (left panel)
and western blot analysis (right panel) of the three NF-Y subunits in
control or NF-YB2 transfected cells. (D) Chromatin immunoprecipita-
tion analysis of NF-Y targets, using control and NF-YB-silenced
HCT116 cells with NF-YB and Flag antibodies.
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in the two NF-YA isoforms, as shown by RT-PCR
analysis (Figure 1C, left panel). Consistent with this,
western blots showed increased NF-YC levels, and no
change for NF-YA (Figure 1C, right panel and
Supplementary Figure 1A). Finally, to ascertain whether
NF-Y binding was affected in RNAi inactivated cells,
ChIP assays with the anti-NF-YB antibody were per-
formed. As shown in Figure 1D, NF-YB siRNA reduces
considerably the binding to CCNB2, Cdc2, Cdc25C and
TK promoters. The PCR of each ChIP were quantitatively
compared to a Flag control antibody (Supplementary
Figure 2A). We conclude that effective inactivation of
NF-YB can be achieved in HCT116 cells.
NF-YB silencing induces depletion in G2/M and apoptosis
The effect of NF-Y inactivation on cellular physiology was
investigated by flow cytometry after siRNA treatment: the
most notable change was a decrease in cells in the G2/M
phase, from 19.2% to 6.7% (Figure 2A). This is not
accompanied by a concomitant increase of cells in G1.
Unexpectedly, hyplodiploid sub-G1 events, evaluated
after propidium iodide staining, increased from 3.4% to
16.7%. This might be due to induction of apoptosis: the
annexin V staining of negative control and NF-YB
siRNA-treated cells, followed by FACS analysis, indeed
showed a parallel increase—from 3% to 15%—in annexin
V positive cells, confirming that these cells are undergoing
apoptosis (Figure 2B). A second siRNA (NF-YB3) has
been used to confirm that NF-YB depletion impairs G2/M
progression and induces apoptosis (Supplementary
Figure 1B). In addition the same cell cycle alterations
after NF-YB silencing has been observed in the human
chondrosarcoma cell line SW1353 (Supplementary
Figure 3A).
In parallel, we performed expression profiling analysis
of cells transfected with negative control and NF-YB
RNAi oligos, with the Affymetrix HG-U133 plus2.0
platform, containing 47 000 transcripts. Using relatively
stringent criteria, 478 genes were down-regulated and 803
were up-regulated. For the repressed genes, we found that
cell cycle, microtubule cytoskeleton and DNA metabolism
are the statistically most important functions (Gene
Ontology enrichment analysis) (Figure 3A). The list of
cell cycle-microtubule cytoskeleton and G2/M genes is
shown in Figure 3B. All of these categories are expected,
given the functional role of NF-Y. On the other hand,
apoptosis is not an over-represented category, with the
only significant changes being an up-regulation of FADD,
Caspase-9, IFM2 and FASTK. Furthermore, setting the
FDR threshold to 12.3%, we found other potential
candidates as anti-apoptotic genes regulated by NF-Y:
BAG3, AERHGDIA, BRE, PIK3R2, BDNF, according
to the expression profiling experiments of Figure 3.
The profiling analysis was validated by RT-PCR,
focusing on CCAAT-promoters regulated during the cell
cycle. As shown in Figure 4A, all the G2/M promoters
analyzed—CCNB2, CCNB1, Cdc25C, Cdc2, Topoisomer-
ase IIa—revealed an evident decrease in transcription.
Western blot analysis of whole cell extracts showed that
CyclinB1, but not CyclinA protein levels, was drastically
reduced upon NF-YB knockdown (Figure 4B). On the
other hand, the transcription of many genes involved in
G1/S transition was not impaired by NF-YB silencing:
CCND1, CCNE, CCNA2; conversely TK1 and DHFR
decreased, suggesting some differential behavior within
this class. The validation by RT-PCR analysis was further
performed by transfecting a second NF-YB siRNA
(NF-YB3) (Supplementary Figure 1A, right panel). In
conclusion, results from profiling data help us explain the
G2/M depletion phenotype of NF-YB inactivated cells,
indicating that a generalized defect in transcription of
G2/M genes is responsible for it.
NF-YB silencing induces caspase dependent apoptosis
To explain the role of NF-Y inactivation in the induction
of apoptosis, we turned our attention to caspases, because
their cleavage and activation play a central role in the
initiation and execution of this process. We first examined
whether apoptosis is a caspase-dependent phenomenon in
NF-YB-inactivated HCT116, treating them with the
broad-spectrum caspase inhibitor Z-VAD. Figure 5A
shows that apoptosis was significantly reduced in the
presence of Z-VAD. A dramatic decrease in sub-G1 cells is
indeed observed, associated to a modest increase in G1
cells. Western blot analysis confirmed that NF-YB protein
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Figure 2. Cell cycle progression in HCT116 NF-YB-silenced cells.
(A) Cell cycle distribution analysis via flow cytometry of HCT116 cells,
transfected NF-YB and non-targeting control siRNA. (B) Apoptosis
was determined by staining with annexin V; the values represent the
portion of annexin V staining cells. Error bars indicate standard
deviations.
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levels were drastically reduced both in untreated and in
Z-VAD-treated cells (Figure 5B), ruling out that the lack
of apoptosis is due to inefficient NF-YB inactivation.
We examined by RT-PCR the mRNA levels of caspase
genes, before and after siRNA transfection. Figure 5C
shows no change for caspase 6 and 7, and a modest
increase for caspase 3, 8 and 9, the latter also emerging
from the profiling data. Traditionally, caspases activity is
determined by the cleavage of pro-caspases into active
caspases. Thus, we performed immunofluorescence in
Up-regulated functional classes
GO ID Term Name genes p-value ratio
GO:0005739 mitochondrion 45 1,34E-06 2,1
GO:0051186 cofactor metabolism 18 6,70E-06 3,1
GO:0006099 tricarboxylic acid cycle 5 1,18E-04 6,1
GO:0044262 cellular carbohydrate metabolism 23 2,37E-04 2,1
7
M PHASE OF CELL CYCLE - SAM FDR 25% 
Entrez Symbol Name
10051 SMC4L1 SMC4 STRUCTURAL MAINTENANCE OF CHROMOSOMES 4-LIKE 1 (YEAST)
10403 KNTC2 KINETOCHORE ASSOCIATED 2
10615 SPAG5 SPERM ASSOCIATED ANTIGEN 5
1063 CENPF CENTROMERE PROTEIN F, 350/400KA (MITOSIN)
NUDC
A B
GO:0046483 heterocycle metabolism 5,98E-04 3,6
GO:0006289 nucleotide-excision repair 4 8,88E-04 5,1
GO:0016192 vesicle-mediated transport 30 5,91E-06 2,3
GO:0048193 Golgi vesicle transport 13 2,07E-05 3,5
GO:0046903 secretion 22 4,61E-05 2,4
GO:0015031 protein transport 37 5,29E-05 1,9
GO:0016197 endosome transport 5 2,47E-04 5,4
GO:0005764 lysosome 13 7,72E-05 3,1
GO:0005768 endosome 9 1,74E-04 3,6
GO:0043123 positive regulation of I-kappaB 11 1,87E-05 4,0
GO:0007264 small GTPase mediated signal transd. 24 2,40E-04 2,1
GO:0007242 intracellular signaling cascade 58 9,96E-04 1,5
GO:0043037 translation 14 8,22E-04 2,4
10726 NUNUCLEAR DISTRIBUTION GENE C HOMOLOG (A. NIDULANS)
11004 KIF2C KINESIN FAMILY MEMBER 2C
259266 ASPM HYPOTHETICAL PROTEIN FLJ10517
332 BIRC5 BACULOVIRAL IAP REPEAT-CONTAINING 5 (SURVIVIN)
3832 KIF11 KINESIN FAMILY MEMBER 11
3835 KIF22 KINESIN FAMILY MEMBER 22
3838 KPNA2 KARYOPHERIN ALPHA 2 (RAG COHORT 1, IMPORTIN ALPHA 1)
4085 MAD2L1 MAD2 MITOTIC ARREST DEFICIENT-LIKE 1 (YEAST)
54443 ANLN ANILLIN, ACTIN BINDING PROTEIN (SCRAPS HOMOLOG, DROSOPHILA)
55143 CDCA8 CELL DIVISION CYCLE ASSOCIATED 8
55165 CEP55 CENTROSOMAL PROTEIN 55KDA
5888 RAD51 RAD51 HOMOLOG (RECA HOMOLOG, E. COLI) (S. CEREVISIAE)
64151 HCAP-G CHROMOSOME CONDENSATION PROTEIN G
6790 AURKA AURORA KINASE A
699 BUB1 BUB1 BUDDING UNINHIBITED BY BENZIMIDAZOLES 1 HOMOLOG (YEAST)
701 BUB1B BUB1 BUDDING UNINHIBITED BY BENZIMIDAZOLES 1 HOMOLOG BETA (YEAST)
7013 TERF1 TELOMERIC REPEAT BINDING FACTOR (NIMA-INTERACTING) 1
Down-regulated functional classes
GO ID Term Name genes p-value ratio
GO:0007049 cell cycle 60 4,65E-22 4,2
GO:0000279 M phase 31 1,31E-19 7,6
GO:0006259 DNA metabolism 44 2,47E-14 3,7
GO:0005694 chromosome 30 2,15E-15 5,7
GO:0006260 DNA replication 23 2,24E-14 7,0
GO:0006281 DNA repair 19 1,30E-08 4,4
GO:0015630 microtubule cytoskeleton 25 8,89E-12 4,9
GO:0000226
microtubule cytoskeleton 
organization and biogenesis 11 1,18E-09 9,6
GO:0005856 cytoskeleton 41 1,16E-08 2,6
GO:0006974 resp. to DNA damage stimulus 23 2,35E-10 4,6
7272 TTK TTK PROTEIN KINASE
8243 SMC1L1 SMC1 STRUCTURAL MAINTENANCE OF CHROMOSOMES 1-LIKE 1 (YEAST)
891 CCNB1 CYCLIN B1
901 CCNG2 CYCLIN G2
9133 CCNB2 CYCLIN B2
9232 PTTG1 PITUITARY TUMOR-TRANSFORMING 1
9700 ESPL1 EXTRA SPINDLE POLES LIKE 1 (S. CEREVISIAE)
9787 DLG7 DISCS, LARGE HOMOLOG 7 (DROSOPHILA)
991 CDC20 CDC20 CELL DIVISION CYCLE 20 HOMOLOG (S. CEREVISIAE)
CELL CYCLE MICROTUBULE CYTOSKELETON GENES - SAM FDR 25%
Entrez Symbol Name
10615 SPAG5 SPERM ASSOCIATED ANTIGEN 5
1063 CENPF CENTROMERE PROTEIN F, 350/400KA (MITOSIN)
10726 NUDC NUCLEAR DISTRIBUTION GENE C HOMOLOG (A. NIDULANS)
11004 KIF2C KINESIN FAMILY MEMBER 2C
CKAP2GO:0046907 intracellular transport 37 1,69E-10 3,2
GO:0015031 protein transport 31 9,01E-08 2,8
GO:0048193 Golgi vesicle transport 8 3,14E-04 3,7
GO:0016071 mRNA metabolism 15 4,34E-05 3,0
GO:0006396 RNA processing 18 5,33E-04 2,2
GO:0005783 endoplasmic reticulum 26 2,00E-05 2,4
GO:0006457 protein folding 12 3,35E-04 2,9
GO:0051082 unfolded protein binding 10 3,89E-04 3,1
GO:0005739 mitochondrion 28 2,61E-05 2,2
GO:0009055 electron carrier activity 12 5,47E-05 3,4
GO:0005516 calmodulin binding 8 8,35E-04 3,2
26586 CYTOSKELETON ASSOCIATED PROTEIN 2
29127 RACGAP1 RAC GTPASE ACTIVATING PROTEIN 1
332 BIRC5 BACULOVIRAL IAP REPEAT-CONTAINING 5 (SURVIVIN)
3832 KIF11 KINESIN FAMILY MEMBER 11
3835 KIF22 KINESIN FAMILY MEMBER 22
51512 GTSE1 G-2 AND S-PHASE EXPRESSED 1
6790 AURKA AURORA KINASE A
699 BUB1 BUB1 BUDDING UNINHIBITED BY BENZIMIDAZOLES 1 HOMOLOG (YEAST)
701 BUB1B BUB1 BUDDING UNINHIBITED BY BENZIMIDAZOLES 1 HOMOLOG BETA (YEAST)
7272 TTK TTK PROTEIN KINASE
9055 PRC1 PROTEIN REGULATOR OF CYTOKINESIS 1
9700 ESPL1 EXTRA SPINDLE POLES LIKE 1 (S. CEREVISIAE)
9787 DLG7 DISCS, LARGE HOMOLOG 7 (DROSOPHILA)
991 CDC20 CDC20 CELL DIVISION CYCLE 20 HOMOLOG (S. CEREVISIAE)
Figure 3. Microarray data analysis. (A) Gene Ontology terms displaying a statistically significant over-representation in the sample-set (up- and
down-regulated genes, respectively). Parameter ‘genes’ is the number of genes annotated by the corresponding term in the sample set; parameter
‘P-value’ refers to the over-representation (see Methods section for statistical details); parameter ‘ratio’ is calculated as the ratio between term
frequency in the sample set versus the universe set (all microarray genes). Terms have been pruned, and then grouped according to manually
determined macro-categories, identified by different colors: see the legend for the categories names; categories with similar colors are functionally
related. (B) Down-regulated genes, annotated by GO terms ‘M Phase’, both ‘Cell Cycle’ and ‘Microtubule Cytoskeleton’. IDs are expressed
according to NCBI Entrez Gene.
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HCT116 cells stained with antibodies specific for cleaved
Caspase 3, 6, 7 and 8. Upon transfection of NF-YB
siRNA, the cleavage of caspase 3, 7 and 8 was activated,
while that of caspase 6 was not (Figure 5D). Thus, NF-YB
inactivation leads to caspases cleavage, and the complete
inhibition of caspase activity by Z-VAD prevent apoptosis
induced by NF-YB depletion.
Role of p53 in apoptosis induction upon NF-YB silencing
In vivo data indicate that NF-Y and p53 are strictly
connected in the control of cell cycle progression upon
DNA damage (24–26). A possible explanation for the
apoptotic behavior of NF-YB inactivated cells would be
activation of p53. To investigate this, we first performed
RT-PCR analysis of the p53 gene: Figure 6A shows a
modest, but reproducible, p53 induction both at the
mRNA and protein levels. The increase of p53 expression
was confirmed by immunofluorescence: Figure 6B (left
panel) shows positive p53 staining in HCT116 NF-YB
inactivated cells, compared to control cells. p53 activation
was further detected by transfecting a second siRNA
(NF-YB3) and two different shRNAs (shRNA NF-YB1
and NF-YB2) in HCT116 (Supplementary Figure 1A,
right panel and Supplementary Figure 1C). In addition we
confirmed p53 transcriptional activation in the human
chondrosarcoma cell line SW1353 (Supplementary
Figure 3B). As for p53 target genes, induction was seen
for Bax and the BH3-only family members, such as Puma,
Noxa and BIK, as well as the CDK inhibitors p21Waf1/
Cip1 and p27 (Figure 6A, left panel). The expression level
of BAD did not change. We also investigated Bcl-2 family
members that inhibit apoptosis, Bcl-2 and Bcl-XL: as
shown in Figure 6A, transcription of these genes was
reduced. Another anti-apoptotic gene is Bax-inibitor
1 (BI-1), regulator of cell death pathways controlled by
Bcl-2 and Bax. RT-PCR analysis showed a decrease of
BI-1 transcription (Figure 6A).
It is well known that p53 activation follows DNA
damage, as well as other noxious stimuli. It has been
reported recently that NF-Y is involved in regulating
Figure 4. Expression analysis of NF-Y targets in NF-YB-silenced HCT116 cells. (A) RNA expression levels of the indicated NF-Y target genes
relative to RNA levels in control and NF-YB-silenced cells (left panel). Quantification of the RT-PCRs, relative to control siRNA expression levels,
is plotted in the right panel. Error bars indicate standard deviations. (B) Cyclin A and Cyclin B1 expression analysis of total extracts of HCT116
non-targeting control or NF-YB siRNA transfected cells.
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many genes of the DNA damage response (33), a notion
confirmed by our profiling experiments (Figure 3). Thus,
one possible explanation for the above results would be
that NF-YB inactivation leads to DNA damage. To
investigate whether this is the case, we used a sensitive
immunofluorescence assay with an antibody against
H2AX, a sensitive marker of activation of the DNA-
damage response: no staining could be detected after
NF-YB inactivation (Figure 6B, right panel), whereas
positivity was readily observed in cells treated with the
DNA-damaging agent Adriamycin. Phosphorylation of
p53 at residue Ser15 has been shown to occur in response
to DNA damage (34,35). Such Ser15 phosphorylation is
catalyzed by multiple protein kinases, including ATM,
which may be activated by different types of damages.
Western blot analysis of the cell lysates from control
and NF-YB siRNA-transfected cells compared to
Adriamycin-treated cells revealed that NF-YB depletion,
unlike Adriamycin, did not cause p53 phosphorylation at
Ser15 (Figure 6C). Therefore, NF-YB inactivation is not
associated to an overt DNA-damage event.
p53 activation is accompanied by post-translational
modifications; among others, acetylations are associated
to p53 functional activation and DNA-binding. To
ascertain whether this is the case in our system, we
performed ChIP analysis with anti-p53, anti-acetyl-K320-
p53, anti-acetyl-K373-382-p53 and control antibodies in
HCT116 and NF-YB-inactivated cells. Figure 6D indeed
shows p53 recruitment on Bax and Mdm2 upon NF-Y
silencing; importantly, p53 is efficiently acetylated at K320
and K373-382. In addition to Bax and Mdm2, the Bcl-2
promoter also showed recruitment of p53, specifically
acetylated at K320. Overall, these data prove that
functional inactivation of NF-YB leads to p53 acetylation,
Figure 5. NF-YB silencing induces apoptosis via caspases activation. (A) Cell cycle distribution analysis via flow cytometry of non-targeting control
and NF-YB siRNA transfected cells, untreated or treated with ZVAD. (B) Western blot analysis of negative control and NF-YB-silenced HCT116
total extracts with anti-NF-YB and anti-actin antibodies, untreated or treated with ZVAD. (C) Expression analysis (RT-PCR) of the indicated
caspase mRNA transcripts. (D) Immunofluorescence analysis of the indicated cleaved caspases and HOECHST.
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Figure 6. Activation of p53 and its target genes upon NF-YB silencing. (A) Left panel: RT-PCR analysis of the indicated mRNA transcripts in
control and NF-YB-silenced cells. RNA expression levels of the indicated genes are quantitated relative to control siRNA transfected cells (lower
right panel). Upper right panel: total extracts subjected to western immunoblotting using anti-p53, anti-bax and anti-actin antibodies. (B) Left panel:
p53 and HOECHST staining of non-targeting control and NF-YB siRNA-transfected cells. Right panel: DNA damage was detected by H2AX
staining of negative control and NF-YB siRNA transfected and Adriamycin-treated HCT116 cells. (C) Western blot analysis with anti-phospho Ser15
p53 and anti-actin antibodies of cell lysates from control siRNA, Adriamycin-treated and NF-YB siRNA-transfected cells. (D) ChIP assays of
control and NF-YB-silenced cells of Bax, Mdm2 and Bcl-2 promoters, with the indicated antibodies. (E) Chromatin of control and NF-YB-silenced
cells was immunoprecipitated with anti-NF-YB and Flag antibodies. PCR amplifications were performed with primers for BI-1 proximal promoter,
BI-1 upstream promoter and Bcl-2. (F) Dose–response analysis (100–300 ng) of NF-YA DN in HCT116 cells with BI-1 and Bcl-2 reporters. Error
bars indicate standard deviations.
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increased DNA-binding to pro-apoptotic promoters and
increased expression of these genes.
Role of NF-Y in the control of anti-apoptotic genes
Many anti-apoptotic genes contain CCAAT boxes. As a
way to explain the anti-apoptotic behavior of NF-YB,
ChIP analysis confirmed NF-Y binding to the core
promoter of the anti-apoptotic BI-1 and Bcl-2 CCAAT
promoters (Figure 6E). Control amplifications of
upstream regions were negative. The PCR of each ChIP
were quantitatively compared to the Flag control anti-
body (Supplementary Figure 2B). Indeed, NF-YB silen-
cing decreased NF-Y binding, a result that parallels the
reduced transcription observed in RT-PCR analysis
(Figure 6A). To unambiguously prove the role of NF-Y
in BI-1 and Bcl-2 transcription, we co-transfected
HCT116 cells with the BI-1-luciferase and Bcl2-luciferase
vectors, together with increasing amounts of the highly
diagnostic dominant negative NF-YA vector YA13m29.
This vector expresses a mutant NF-YA subunit that still
enables NF-YB/NF-YC dimer interaction, but renders the
resulting trimer inactive in CCAAT recognition (36).
Figure 6F shows that the DN vector is indeed inhibitory
on both promoters. These data indicate that NF-Y
silencing leads to down-regulation of anti-apoptotic genes.
p53 is necessary for the apoptotic response upon NF-Y
knockdown
To detail the role of p53 and its target genes in apoptosis,
we switched to HCT116/E6 cells, in which p53 is
inactivated by expression of the E6 protein (37–40).
A significant reduction of NF-YB levels was achieved
(Figure 7A) and FACS analysis shows an increase in cells
in G1, and a modest decrease in S and G2/M cells
(Figure 7B). Comparison with FACS analysis of HCT116
cells in Figure 2A highlights that the decrease in G2/M is
not as efficient as with p53-positive cells, confirming the
role of p53 in G2/M depletion. Moreover, hyplodiploid
sub-G1 events were essentially absent—from 1.4% to
2%—indicating that p53 is necessary to induce apoptosis
by NF-YB inactivation. mRNA levels of cell-cycle
regulated genes were evaluated by RT-PCR (Figure 7C,
left panel). As expected, NF-YB siRNA transfection
induced a reproducible decrease of NF-YB; G2/M
promoters regulated by NF-Y were modestly decreased
compared to HCT116. p21 and p27 did not increase and
no change was seen for BH3-only Bik and Bax
(Figure 7C), as confirmed by western blot analysis
(Figure 7C, right panel); the anti-apoptotic Bcl-XL also
showed no decrease. However, the transcription level of
Bcl-2a and BI-1 were efficiently reduced, comparable to
that of p53-positive cells (Figure 7C, left panel). To
investigate whether this inhibition is a direct effect of
NF-YB depletion on the promoter activity, we transiently
co-transfected the Bcl-2a-luciferase vector together with
increasing amounts of NF-Y trimer in HCT116/E6 cells.
Figure 7D shows that the NF-Y expression activates the
transcription of the Bcl-2a promoter.
What is particularly relevant are the mRNA ratios of
pro- versus anti-apoptotic Bcl-2 family members, Bax to
Bcl-2 and to Bcl-XL, in HCT116 and HCT116/E6 NF-YB-
silenced cells, which is shown in Figure 7E. The Bax/Bcl-2
and Bax/Bcl-XL ratios are skewed toward Bax in HCT116
cells; interestingly, the former remains increased in
HCT116/E6, by virtue of lack of Bax activation and Bcl-
2 decrease, whereas the Bax/Bcl-XL ratio drops consider-
ably in the absence of p53 and NF-YB, due to increase in
Bcl-XL. These data provide evidence that p53 is required
in the apoptotic response upon NF-Y RNAi, suggesting
that decreased levels of anti-apoptotic genes are not
sufficient to induce apoptosis, as pro-apoptotic members
of the Bcl-2 family activated by p53 play a significant role
in this phenomenon.
To futher investigate the role of NF-Y in preventing
apoptosis, we overexpressed the NF-Y trimer in HCT116
cells and we activated p53 by Adriamycin treatment after
24 h. As shown in Figure 8A, NF-Y reduces apoptosis
activation mediated by p53. RT-PCR and western Blot
analysis confirm an increase in p53 mRNA and protein
levels, which is reverted by NF-Y overexpression
(Figure 8B). In addition, Bcl2 repression after
Adriamycin treatment is reversed by transfecting NF-Y,
and Bax activation is—modestly—reduced. NF-Y over-
expression correlates with decreasing ratios of Bax to Bcl2
(Figure 8C). Finally, the increase in cytochrome C release
into the cytoplasm after ADR is obliterated by NF-Y
overexpression (Figure 8D). We conclude that increasing
the levels of NF-Y protects cells from entering a p53-
mediated pathway of apoptosis.
DISCUSSION
NF-Y targets include regulatory genes that ensure orderly
progression of the cell cycle. Over the last years, many
efforts have been made to establish the role of NF-Y in
controlling cell proliferation in vivo (18,28,29). In this
study, we examined the effects of knocking down the
NF-YB subunit for cell cycle progression. Three relevant
findings are presented: (i) NF-Y silencing impairs G2/M
progression and induces apoptosis; (ii) widespread activa-
tion of G2/M and anti-apoptotic genes requires NF-Y;
(iii) p53 is activated by a decrease in NF-YB and it
is involved in cell cycle alteration and programmed
cell death.
NF-Y silencing impairs G2/M progression and induces
apoptosis
We have determined that RNAi-mediated depletion of the
NF-YB subunit can induce cell cycle progression failure,
resulting in impairment of the G2/M transition
(Figure 2A). Our results showed a massive delay in
mitotic progression. Importantly, >60% of cells failed to
progress through G2/M during a 48 h observation period,
whereas only a small proportion of cells is impaired in
progression to S phase. RT-PCR analysis confirmed a
decrease in transcription of G2/M-regulated genes after
NF-YB knockdown (Figure 4), nevertheless we cannot
exclude that factors outside of the transcriptional appa-
ratus contribute significantly to the G2/M depletion effect.
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Two bioinformatic studies on CCAAT boxes link them
to cell cycle regulation: the analysis of cell cycle promoters
showed a remarkable and specific abundance of
CCAAT boxes in promoters regulated during the G2/M
phase (17) and the recent development of a computa-
tional algorithm to identify transcription factors that
preferentially act together, identified the NF-Y-CDE-
CHR module as predictive of G2/M genes (41). CDE-
CHR elements are cis-regulatory sequences originally
characterized in genetic experiments for their import-
ance in restricting expression in G2 and M (42,43).
Our profiling analysis indicates that genes of G2 and M
Figure 7. Role of p53 in apoptosis induction. (A) Expression levels of NF-YB and actin in HCT116/E6 upon NF-YB silencing. (B) Cell cycle
progression analysis by FACS of control and NF-YB-silenced HCT116/E6 cells. Error bars indicate standard deviations. (C) Left panel: RT-PCR
analysis of G2/M, pro- and anti-apoptotic genes upon NF-YB siRNA transfection. PCR amplified genes are indicated and their quantitation, relative
to control expression levels, is plotted in the right lower panel. Right upper panel: total extracts subjected to western immunoblotting using anti-bax
and anti-actin antibodies. (D) Dose–response analysis (50–100 ng) of NF-Y in HCT116/E6 cells with Bcl-2 reporter. Error bars indicate standard
deviations. (E) The histogram represents the Bax/Bcl-2 and Bax/Bcl-XL mRNA ratios in HCT116 and HCT116/E6 NF-YB-silenced cells.
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phases are hit, as well as those required for microtubule,
cytoskeleton and spindle formation, occurring during G2,
and, in general, required for mitotic entry. Therefore,
these experiments represent the molecular basis for the
bioinformatic predictions. They also support the conclu-
sion that the cell cycle depletion is due to a generalized
requirement for NF-Y in genes expressed in G2 and M,
rather than to specific G2/M regulators, such as CDC25C,
Cyclin B1, Cdc2 and AuroraB.
Two different approaches were used to gather func-
tional information about pathways regulated by NF-Y/
CBF, by targeting NF-YA/CBF-B, a different subunit
from the one analyzed here. (i) The CBF-B/NF-YA gene
was inactivated in ES cells and KO mice derived: they die
early in embryogenesis and inactivation in primary mouse
embryonic fibroblasts results in a block in cell prolifera-
tion and inhibition of S phase or DNA synthesis, followed
by induction of apoptosis. This latter event, however,
was a very late phenomenon, being manifest after 5 days
(28). (ii) Overexpression of an inducible Dominant
Negative CBF-B/NF-YA lacking the transcription
activation domain (Bdbd) showed a dramatic arrest in
G2/M and lack of expression of G2/M genes (29,44).
No apoptosis was observed. The results presented for
NF-YB inactivation are quite different and there are two
possible scenarios.
One possibility focuses on the special relationship
between NF-Y and p53 as a transcriptional G2/M
checkpoint ‘duo’, described with a different NF-YA
Dominant Negative mutated in the DNA-binding sub-
domain (YAm29). This DN inhibited the p53 response,
notably a G2/M block, both in cells with wt p53 and with
tumor derived p53 mutants (24,25). The YAm29 and
Bdbd act in fundamentally different ways: the latter
associates with the NF-YB/NF-YC heterotrimer, binds
DNA, but it does not activate transcription, due to lack of
the Q-rich activation domain. The mechanism is most
likely related to the lack of recruitment of general
transcription factors (44). The former inhibits DNA
binding of the trimer, by forming a defective heterotrimer,
which is incapable to associate with DNA. This removes
p53 from G2/M promoters, possibly unlike Dbdb. In this
scheme, apoptosis would result from the transcriptional
block and the release of p53 from G2/M promoters; with
Bdbd, instead, NF-Y stays on the promoter and might
keep p53 bound: only a transcriptional block would ensue,
without the accompanying p53 activation.
Alternatively, it is possible that the three different
subunits have somewhat specialized roles in different sets
of genes. NF-YA has no histone-like structure, unlike
NF-YB-NF-YC, whose resemblance to H2A-H2B has
been detailed by chrystallography: it is possible that the
elimination—or unbalance—of the histone-fold dimer
might bring a more serious threat to cell survival and
trigger a prompt apoptotic response. Indeed, there are
tissues in vivo in which NF-YA, but not NF-YB, is
apparently absent (21,45), suggesting a more ‘structural’
role for the heterodimer. We also note that the NF-YB/
NF-YC heterodimer is 2/3-fold in excess with respect of
NF-YA in growing cells (Salvatoni,S. and Mantovani,R.,
unpublished data). The dimer might thus be involved in
connections other than CCAAT binding and transcrip-
tional regulation.
In agreement with previous studies, there is no G1/S
block upon NF-YB inactivation. In general, this is
surprising, considering the number of G1/S genes that
are functioning through NF-Y, including some of the key
regulators of S phase entry (11,18,46,47). The profiling
analysis supports the idea that transcription of G1/S genes
is less dependent on NF-Y. It is possible that the complete
elimination of NF-YB, as opposed to the 80–90%
reduction of protein levels reported here, could cause
additional G1/S phenotypes not detected in this study.
Figure 8. Overexpression of NF-Y prevents p53-mediated apoptosis.
(A) Apoptosis fold activation in control cells and in NF-Y over-
expressing cells concurrently with Adriamycin treatment. Error bars
indicate standard deviations. (B) Left panel: RT-PCR analysis of p53,
Bax and Bcl-2 genes upon Adriamycin and NF-Y overexpression
concurrently with Adriamycin treatment. Right panel: the histogram
represents the Bax/Bcl-2 mRNA ratios in Adriamycin and NF-Y
overexpressing/Adriamycin-treated cells. Error bars indicate standard
deviations. (C) Upper panel: total extracts subjected to western
immunoblotting using anti-actin, anti-NF-YB and anti-p53 antibodies.
Lower panel: isolated cytosolic fractions of control, Adriamycin and
NF-Y overexpressing/Adriamycin-treated cells, subjected to western
blot analysis with anti-cytochrome C antibody.
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p53-NF-Y: a special connection ?
The connections between p53 and NF-Y were known
before. In fact, it has been shown that the two factors
interact directly, both with wt p53 and in tumor cells with
mutant p53 alleles (24,25). Regions within the two
proteins have been pinpointed that mediate interactions:
the C-terminus of p53 and the aC of NF-YC. Under
unstressed conditions, p53 is bound to G2/M promoters
and the importance of this G2/M transcriptional ‘check-
point’ is highlighted by the findings that gain-of-function
p53 mutants subvert it completely, promoting transcrip-
tion of key cell cycle regulators. Indeed, such p53 mutants
show a stronger inherent interaction with NF-Y (25).
p53 activation occurs normally under stressed condi-
tions, specifically after DNA damage, and modulation of
p53 activity is exerted via post-translational modifications
(48). The sensitive H2AX assay, which is commonly used
to monitor cells that undergo DNA lesions, and the lack
of p53-Ser15 phosphorylation, suggest that removal of
NF-YB does not cause DNA damage. Thus, activation of
p53 is an apparently surprising result. Our ChIP assays
further indicate that it is an acetylated, ‘active’ p53 that
binds to the target promoters. There are two possibilities.
(i) The p53-NF-Y duo, positioned on G2/M genes might
be a sensor of stress (see above). The link between the two
proteins could be direct, as revealed by protein–protein
interaction assays, or mediated by other factors. Removal
of p53 from its ‘niche’ G2/M promoters by NF-Y
depletion, might trigger exposure of specific p53 residues
and activation of the protein. An interacting partner
might mask p53 residues, as long as the NF-Y-p53
interaction is intact. (ii) Alternatively, one should consider
that NF-Y is a key factor in the transcriptional response
to numerous stress signals (8,49). NF-YB inactivation
could be ‘sensed’ as a potentially dangerous situation
simply because stress responses, which play a fundamental
role in cell survival, would be highly diminished. Two
groups of genes come to mind: the first are genes coding
for proteins required in various DNA-damage responses,
which are under NF-Y control. This has been detailed in
ChIP on chip experiments with an oligo array enriched in
this category (33). Most of these genes are actually not
induced by the damage, and they are expressed at low,
constant levels. The second group is genes that mediate the
response to Endoplasmic Reticulum stress: most of these
genes are strongly dependent on NF-Y (49 and references
therein). Falling short on a minimum of expression of
these genes, or closing down their promoter accessibility,
as it is the case when NF-Y is not bound, could be sensed
as a stress condition, triggering an indirect p53 activation.
Mechanisms of activation of apoptosis
The p53-inducible proapoptotic genes are involved in
several death pathways (50). Activated p53 induces the
transcription of apoptotic genes such as Bax (51), Puma
(52), Noxa (53), p53AIP (54), FAS/APO1 (55) and
represses the anti-apoptotic Bcl-2 (56). CDK inhibitors
p21 and p27 are transcriptionally activated by NF-YB
knockdown, as well as Bax and the BH3-only Bik, Puma
and Noxa (Figure 6A). The analysis of both cell cycle
progression and of the activation of p53 target genes in
HCT116/E6 cells indicates that p53 is required for the
apoptotic response. Our results imply that p53 is involved
in activating pro-apoptotic target genes by directly
binding to their promoters. Interestingly, the analysis of
p53 targets—Bax, Mdm2 and Bcl2—by ChIP assays
showed that p53 is differently acetylated. The activated
promoters, Bax and Mdm2, are positive for p53 acetyla-
tion at both Lys320 and Lys 373-382, while the repressed
Bcl2 promoter showed a recruitment of p53 specifically
acetylated at Lys320.
Downstream of p53, the Bcl-2 family members play a
role in apoptosis. The translocation of p53 to the
mitochondria and the formation of complexes with the
anti-apoptotic Bcl-2 family proteins induce the release of
sequestered pro-apoptotic proteins and subsequent per-
meabilization of the outer mitochondrial membrane
(53–57). NF-YB inactivation correlates with the cleavage
of procaspase-3, 7 and 8 and an increase in Bax/Bcl-2 and
Bax/Bcl-XL ratios. The overexpression of anti-apoptotic
Bcl-2 family proteins, such as Bcl-2 and Bcl-XL, blocks the
release of cytochrome c in response to a variety of
apoptotic signals (58). On the contrary, the relocalization
of Bax to mitochondria is linked to increased cytochrome
c levels in the cytosol (58–60). The comparison between
HCT116 and HCT116/E6 data clearly suggests that
inhibition of the anti-apoptotic Bcl-2a and BI-1 is due to
NF-Y inactivation (Figure 7). This highlights the impor-
tance of a fine balance between p53 and NF-Y-regulated
genes (Figure 9). NF-Y silencing increases the Bax/Bcl-2
ratio both in HCT116 and in HCT116/E6. In p53 positive
cells, the level of Bax is induced, in the absence of p53 it is
not. Thus, the increase in HCT116/E6 cells is caused by
the failure to activate Bcl-2 as a consequence of NF-Y
knockdown. Conversely, the Bax/Bcl-XL ratio is 3-fold
increased only in HCT116, pointing out that Bcl-XL is a
direct target of p53, but not of NF-Y. Therefore, it seems
reasonable to postulate that apoptosis may be caused by a
reduction in Bcl-XL/Bax heterodimerization. Disruption
of this balance can occur either following a loss NF-Y
activity, or by p53 activation, through DNA damage. The
role of NF-Y in preventing apoptosis has been clearly
demonstrated by comparing the Bax to Bcl2 ratios, after
Adriamycin treatment or NF-Y overexpression concur-
rently with Adriamycin. NF-Y overexpression causes a
decrease in the Bax to Bcl2 ratio, and abrogates the
cytochrome C release into the cytoplasm.
As the expression changes of many of the anti-apoptotic
genes are below the stringent criteria used here in the
profiling analysis, much work lies ahead in the determina-
tion of the complete picture of pro-survival genes
regulated by NF-Y. Finally, the behavior of gain-of-
function p53 mutants should be re-evaluated, in terms of
the enhancement of NF-Y anti-apoptotic and pro-survival
function, which might impact in their pro-growth strategy.
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